Security
Aurora Cannabis Inc. · ACB
ACBTSXCommon stockCurrentCIK 1683541Updated Nov 10, 2026
ACB price & chart
Loading TradingView…
TSX:ACB on TradingView ↗About the company
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
In the news
Aurora Cannabis Inc. Reminds Shareholders to Vote in Advance of the Proxy Voting Deadline for its 2025 Annual General and Special Meeting of Shareholders News provided by Aurora Cannabis Inc. Jul 30, 2025, 07:05 ET Share this article Share to X Share this article Share to X Your vote is important no ↗
Aurora Cannabis Inc. Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General and Special Meeting of Shareholders News provided by Aurora Cannabis Inc. Jul 09, 2025, 07:30 ET Share this article Share to X Share this article Share to X Your vote is imp ↗
Recent filings
Financials
FY 2025 · CADSource
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossCAD | 1,591,000Source | -69,326,000Source | -1,717,979,000Source | -695,089,000Source |
| Additional Financial Items | ||||
| AdjustmentsForSharebasedPaymentsCAD | 11,524,000Source | 12,717,000Source | 13,757,000Source | 20,243,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsCAD | -11,453,000Source | 105,000Source | -1,915,000Source | 3,420,000Source |
| GeneralAndAdministrativeExpenseCAD | 97,257,000Source | 92,222,000Source | 113,212,000Source | 119,437,000Source |
| GoodwillCAD | 43,871,000Source | 43,180,000Source | 0Source | 887,737,000Source |
| IncreaseDecreaseInWorkingCapitalCAD | -10,210,000Source | 15,627,000Source | -52,652,000Source | -397,000Source |
| InterestPaidClassifiedAsOperatingActivitiesCAD | 6,844,000Source | 11,700,000Source | 27,725,000Source | 34,157,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesCAD | 5,240,000Source | 5,627,000Source | 7,545,000Source | 5,416,000Source |
| ProceedsFromIssuingSharesCAD | 0Source | 37,926,000Source | 350,188,000Source | 666,026,000Source |
| ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodCAD | 5,488,000Source | 4,993,000Source | 0Source | — |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesCAD | — | — | 19,648,000Source | 19,241,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesCAD | 7,245,000Source | 3,042,000Source | 0Source | — |
income statement · annual statements
| Line item | Q4 2022 | FY 2025 | FY 2024 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Selling, General and Administrative ExpenseCAD | — | — | 144,159,000Source | 175,237,000Source | — |
| Total RevenueCAD | — | — | — | 221,339,000Source | 245,252,000Source |
| Additional Financial Items | |||||
| ApplicableTaxRatenumber | — | 0.27Source | 0.27Source | 0.27Source | 0.27Source |
| BasicEarningsLossPerShareCAD/shares | — | 0.04Source | -1.52Source | -7.99Source | — |
| CurrentTaxExpenseIncomeCAD | — | 7,808,000Source | 1,109,000Source | 52,000Source | 122,000Source |
| DeferredTaxExpenseIncomeCAD | — | -3,189,000Source | -1,663,000Source | -2,193,000Source | -6,443,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossCAD | — | — | — | — | -6,542,000Source |
| DepreciationAndAmortisationExpenseCAD | — | 9,080,000Source | 12,139,000Source | 48,602,000Source | 49,174,000Source |
| DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssetsCAD | — | 27,445,000Source | — | — | — |
| DilutedEarningsLossPerShareCAD/shares | — | 0.04Source | -1.52Source | -7.99Source | — |
| FinanceCostsCAD | — | 8,420,000Source | 14,186,000Source | 71,813,000Source | 66,437,000Source |
| GainsLossesRecognisedWhenControlInSubsidiaryIsLostCAD | — | — | 0Source | 0Source | 0Source |
| GeneralAndAdministrativeExpenseCAD | — | 97,257,000Source | 92,222,000Source | 113,212,000Source | 119,437,000Source |
| GrossProfitCAD | — | 187,607,000Source | 131,460,000Source | 21,225,000Source | -21,558,000Source |
| ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipmentIncludingRightofuseAssetsCAD | — | 696,000Source | — | — | — |
| IncomeTaxExpenseContinuingOperationsCAD | — | 4,619,000Source | -554,000Source | -2,141,000Source | -6,321,000Source |
| InterestExpenseOnLeaseLiabilitiesCAD | — | 2,921,000Source | 3,152,000Source | 3,433,000Source | 4,597,000Source |
| ProfitLossAttributableToNoncontrollingInterestsCAD | — | — | — | -355,000Source | — |
| ProfitLossAttributableToOwnersOfParentCAD | — | — | — | -1,717,624,000Source | — |
| ProfitLossBeforeTaxCAD | — | 20,382,000Source | -59,599,000Source | -1,720,120,000Source | -699,798,000Source |
| ProfitLossFromOperatingActivitiesCAD | — | 4,948,000Source | -46,453,000Source | -231,449,000Source | -282,818,000Source |
| ResearchAndDevelopmentExpenseCAD | — | 3,676,000Source | 3,572,000Source | 10,389,000Source | 11,447,000Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodCAD | — | — | — | 293,000Source | 509,000Source |
Filing attachments
tm2629252d1_ex99-1.htm · 6-K · 2026-11-09
Exhibit 99.1 Date: November 9, 2026 510 Burrard Street, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com ───────────────────────────────────────────────────────────────────────────────────── To: All Canadian Securities Regulatory Authorities Subject: AURORA CANNABIS INC. Dea…
Read attachment ↗tm2629080d1_ex99-1.htm · 6-K · 2026-11-05
Exhibit 99.1 November 5, 2026 NASDAQ | TSX: ACB ──────────────────────────────────── Aurora Cannabis Announces Fiscal 2027 Second Quarter Results Delivers Net Revenue of $86.0 million, including Record International Medical Cannabis Net Revenue of $61.4 million, representing a 44% YoY Increase Generated Adjusted EBITDA1 of $14.0 million, with Free Cash Flow1 Outflow Improving by $22.4 million Maintains Strong Balance Sheet with $133.0 million of Cash,…
Read attachment ↗tm2628851d1_ex99-1.htm · 6-K · 2026-11-04
Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT Name and Address of Company: ──────────────────────────────── Aurora Cannabis Inc. (“Aurora” or the “Company”) 2207-90B Street SW Edmonton, Alberta T6X 1V8 Date of Material Change: ──────────────────────────── November 2, 2026 News Release: A press release describing the material change was disseminated by Aurora on November 3, 2026 through Business Wire and can be found on SEDAR+ at www.sedarplus.ca. Summary of Material Cha…
Read attachment ↗tm2628851d1_ex99-2.htm · 6-K · 2026-11-04
Exhibit 99.2 SEDAR+ Version ORGANIGRAM GLOBAL INC. - and - AURORA CANNABIS INC. ARRANGEMENT AGREEMENT November 2, 2026 TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 2 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Page …
Read attachment ↗tm2628773d2_ex99-1.htm · 6-K · 2026-11-03
Exhibit 99.1 Organigram to Acquire Aurora and Establish a Global Cannabis Leader Organigram to acquire Aurora for C$7.80 per Aurora Common Share; Aurora shareholders will have the option to receive such Consideration in cash, Organigram shares or a combination of both, subject to proration. Transaction provides Aurora shareholders with certainty of value, meaningful immediate liquidity and participation in the combined entity Offer represents a 93% premium to Aurora’s Unaffected Sha…
Read attachment ↗tm2628516d1_ex99-1.htm · 6-K · 2026-10-29
Exhibit 99.1 October 29, 2026 NASDAQ | TSX: ACB ─────────────────────────────────────────── Aurora Cannabis to Host Second Quarter 2027 Investor Conference Call Edmonton, AB - October 29, 2026 - Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it will host an investor conference call on Thursday, November 12, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time to discuss its…
Read attachment ↗